Highest level of thromboprophylaxis given in Myeloma IX and XI trials, by risk before VTE
| Thromboprophylaxis . | Myeloma IX . | Myeloma XI . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High risk (n = 62) . | Low risk (n = 233) . | Total (N = 295) . | High risk (n = 291) . | Low risk (n = 241) . | Total (N = 532) . | |||||||
| No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | |
| Not given | 42 | 67.7 | 182 | 78.1 | 224 | 75.9 | 40 | 13.7 | 50 | 20.7 | 90 | 16.9 |
| Aspirin | NR | NR | NR | 67 | 23.0 | 80 | 33.2 | 147 | 27.6 | |||
| Treatment dose of warfarin | 9 | 14.5 | 29 | 12.4 | 38 | 12.9 | 11 | 3.8 | 3 | 1.2 | 14 | 2.6 |
| LMWH | 9 | 14.5 | 19 | 8.2 | 28 | 9.5 | 168 | 57.7 | 100 | 41.5 | 268 | 50.4 |
| Other | 1 | 1.6 | 1 | 0.4 | 2 | 0.7 | 4 | 1.4 | 5 | 2.1 | 9 | 1.7 |
| Missing | 1 | 1.6 | 2 | 0.9 | 3 | 1.0 | 1 | 0.3 | 3 | 1.2 | 4 | 0.8 |
| Thromboprophylaxis . | Myeloma IX . | Myeloma XI . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High risk (n = 62) . | Low risk (n = 233) . | Total (N = 295) . | High risk (n = 291) . | Low risk (n = 241) . | Total (N = 532) . | |||||||
| No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | No. . | % . | |
| Not given | 42 | 67.7 | 182 | 78.1 | 224 | 75.9 | 40 | 13.7 | 50 | 20.7 | 90 | 16.9 |
| Aspirin | NR | NR | NR | 67 | 23.0 | 80 | 33.2 | 147 | 27.6 | |||
| Treatment dose of warfarin | 9 | 14.5 | 29 | 12.4 | 38 | 12.9 | 11 | 3.8 | 3 | 1.2 | 14 | 2.6 |
| LMWH | 9 | 14.5 | 19 | 8.2 | 28 | 9.5 | 168 | 57.7 | 100 | 41.5 | 268 | 50.4 |
| Other | 1 | 1.6 | 1 | 0.4 | 2 | 0.7 | 4 | 1.4 | 5 | 2.1 | 9 | 1.7 |
| Missing | 1 | 1.6 | 2 | 0.9 | 3 | 1.0 | 1 | 0.3 | 3 | 1.2 | 4 | 0.8 |